MA31753B1 - Detection amelioree de l'expression de mage-a - Google Patents

Detection amelioree de l'expression de mage-a

Info

Publication number
MA31753B1
MA31753B1 MA32736A MA32736A MA31753B1 MA 31753 B1 MA31753 B1 MA 31753B1 MA 32736 A MA32736 A MA 32736A MA 32736 A MA32736 A MA 32736A MA 31753 B1 MA31753 B1 MA 31753B1
Authority
MA
Morocco
Prior art keywords
mage
gene
primer
expression
methylation
Prior art date
Application number
MA32736A
Other languages
Arabic (ar)
English (en)
Inventor
Ilse Vlassenbroeck
Katja Bierau
Original Assignee
Oncomethylome Sciences Sa
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomethylome Sciences Sa, Glaxosmithkline Biolog Sa filed Critical Oncomethylome Sciences Sa
Publication of MA31753B1 publication Critical patent/MA31753B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/30Oligonucleotides characterised by their secondary structure
    • C12Q2525/301Hairpin oligonucleotides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00Nucleic acid detection characterised by assay method
    • C12Q2561/113Real time assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/10Detection mode being characterised by the assay principle
    • C12Q2565/101Interaction between at least two labels
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE UN OLIGONUCLÉOTIDE, UNE AMORCE OU UNE SONDE COMPRENANT LA SÉQUENCE NUCLÉOTIDIQUE D'UNE QUELCONQUE SEQ ID NO. 5, 6, 7, 2, 3, 4, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19 OU 25. LES OLIGONUCLÉOTIDES SONT UTILISÉS DANS LA DÉTECTION DE L'ÉTAT DE MÉTHYLATION D'UN GÈNE, EN PARTICULIER LE GÈNE MAGE-A3. LES OLIGONUCLÉOTIDES SONT, DE PLUS, UTILISÉS DANS DES PAIRES D'AMORCES, DES KITS ET DES MÉTHODES DE DÉTERMINATION DE L'ÉTAT DE MÉTHYLATION DU GÈNE MAGE-A3 ET DANS LE DIAGNOSTIC DU CANCER, L'ORIENTATION THÉRAPEUTIQUE ET LA SÉLECTION DE SUJETS À DES FINS DE TRAITEMENT. L'AMORCE OU LA SONDE PEUVENT COMPRENDRE UNE STRUCTURE EN BOUCLE OU EN ÉPINGLE À CHEVEUX ET PEUVENT ÊTRE UTILISÉES DANS UNE PCR SPÉCIFIQUE À LA MÉTHYLATION EN TEMPS RÉEL.
MA32736A 2007-09-17 2010-04-01 Detection amelioree de l'expression de mage-a MA31753B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96012807P 2007-09-17 2007-09-17
PCT/GB2008/003142 WO2009037438A1 (fr) 2007-09-17 2008-09-17 Détection améliorée de l'expression de mage-a

Publications (1)

Publication Number Publication Date
MA31753B1 true MA31753B1 (fr) 2010-10-01

Family

ID=40239643

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32736A MA31753B1 (fr) 2007-09-17 2010-04-01 Detection amelioree de l'expression de mage-a

Country Status (18)

Country Link
US (4) US9050280B2 (fr)
EP (2) EP2198045A1 (fr)
JP (1) JP5406839B2 (fr)
KR (1) KR20100085917A (fr)
CN (1) CN101932723B (fr)
AU (1) AU2008300397A1 (fr)
BR (1) BRPI0817008A2 (fr)
CA (2) CA2699853A1 (fr)
CO (1) CO6260156A2 (fr)
CR (1) CR11504A (fr)
DO (1) DOP2010000076A (fr)
EA (1) EA017879B1 (fr)
IL (1) IL204525A0 (fr)
MA (1) MA31753B1 (fr)
MX (1) MX2010002965A (fr)
NZ (2) NZ583796A (fr)
WO (2) WO2009037438A1 (fr)
ZA (1) ZA201001878B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130237445A1 (en) * 2010-09-14 2013-09-12 The University Of North Carolina At Chapel Hill Methods and kits for detecting melanoma
WO2012129488A2 (fr) * 2011-03-23 2012-09-27 Virginia Commonwealth University Signatures géniques associées au rejet ou à la récurrence du cancer
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
CA2897474A1 (fr) 2013-01-24 2014-07-31 California Institute Of Technology Caracterisation a base de chromophore et procedes de detection
US9994911B2 (en) 2013-03-14 2018-06-12 Mayo Foundation For Medical Education And Research Detecting neoplasm
DE112016000293T5 (de) 2015-02-26 2017-09-21 Hitachi High-Technologies Corporation Verfahren zum konstruieren eines nucleinsäure-moleküls
CN105100961B (zh) * 2015-07-23 2018-03-13 华为技术有限公司 视频缩略图生成方法及生成装置
DE102016005947B3 (de) * 2016-05-16 2017-06-08 Dimo Dietrich Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
US10294518B2 (en) 2016-09-16 2019-05-21 Fluxion Biosciences, Inc. Methods and systems for ultra-sensitive detection of genomic alterations
US20200010907A1 (en) 2017-03-17 2020-01-09 Mdxhealth Sa Mgmt epigenetic deep-sequencing assay
US20180271710A1 (en) * 2017-03-22 2018-09-27 Bragi GmbH Wireless earpiece for tinnitus therapy
EP3655418A4 (fr) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
EP3687501A4 (fr) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations
US11441182B2 (en) * 2018-08-08 2022-09-13 Virginia Commonwealth University Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers
CN109540856B (zh) * 2018-11-08 2022-01-28 南京师范大学 一种基于荧光共振能量转移检测不同亚型乳腺癌细胞的试剂
CN111551978B (zh) * 2020-05-08 2022-09-27 中国辐射防护研究院 一种放射性土壤样品采样过程不确定度的评定方法
WO2023108145A1 (fr) * 2021-12-10 2023-06-15 Nuprobe Usa, Inc. Sondes universelles pour l'amplification et la détection d'acides nucléiques
WO2024102722A1 (fr) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Procédés de traitement d'une tumeur avec un promoteur mgmt non méthylé

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
CA1340843C (fr) 1987-07-31 1999-12-07 J. Lawrence Burg Amplification selective de sequences polynucleotidiques cibles
HU216105B (hu) 1988-12-16 1999-04-28 Akzo Nobel N.V. Amplifikációs eljárás önfenntartó szekvenciareplikációs rendszerrel
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167377B2 (fr) 1994-07-15 2012-08-08 University of Iowa Research Foundation Oliogonucléotides immunomodulateurs
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6291430B1 (en) * 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
BR9907691B1 (pt) * 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US6768000B1 (en) 1998-06-12 2004-07-27 Intergen Company Multi-fluorescent hairpin energy transfer oligonucleotides
WO2000009159A1 (fr) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions de cpg et d'adjuvants a base de saponine et leurs procedes d'utilisation
US6667037B1 (en) * 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
JP2004505612A (ja) * 2000-03-31 2004-02-26 ユニバーシティ・オブ・サザン・カリフォルニア 食道腺ガンに関する後成的配列
AU2002312764A1 (en) 2001-03-15 2002-10-21 Schrenzel, Jacques Detection of methicillin-resistant staphylococcus aureus (mrsa)
AU2002360429A1 (en) 2001-11-26 2003-06-10 Avigen, Inc. Methods for producing stocks of recombinant aav virions
CN1301134C (zh) 2002-02-04 2007-02-21 科里克萨有限公司 新的免疫效应化合物
DE10215770A1 (de) * 2002-04-10 2003-10-30 Michael Giesing Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits
WO2004067726A2 (fr) 2003-01-29 2004-08-12 Keck Graduate Institute Reactions isothermes pour amplification d'oligonucleotides
WO2004087957A2 (fr) 2003-04-03 2004-10-14 Oncomethylome Sciences S.A. Genes hypermethyles et cancer du col de l'uterus
US7881873B2 (en) * 2003-04-29 2011-02-01 The Jackson Laboratory Systems and methods for statistical genomic DNA based analysis and evaluation
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
DE10338308B4 (de) * 2003-08-15 2006-10-19 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierungen in DNA
US8062849B2 (en) * 2003-10-28 2011-11-22 The Johns Hopkins University Quantitative multiplex methylation-specific PCR
US20050130170A1 (en) * 2003-12-16 2005-06-16 Jeanne Harvey Identification and verification of methylation marker sequences
AU2005293703B2 (en) * 2004-10-11 2010-02-18 Epigenomics Ag A method for the carry-over protection in DNA amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids
US20070059753A1 (en) * 2005-09-15 2007-03-15 Tatiana Vener Detecting gene methylation
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB0700374D0 (en) * 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
US8911937B2 (en) * 2007-07-19 2014-12-16 Brainreader Aps Method for detecting methylation status by using methylation-independent primers

Also Published As

Publication number Publication date
US8481700B2 (en) 2013-07-09
CA2699856A1 (fr) 2009-03-26
NZ596545A (en) 2013-05-31
EP2201131B8 (fr) 2014-12-10
US20130302363A1 (en) 2013-11-14
US10053724B2 (en) 2018-08-21
NZ583796A (en) 2011-12-22
JP2010538633A (ja) 2010-12-16
KR20100085917A (ko) 2010-07-29
EP2201131A1 (fr) 2010-06-30
US9050280B2 (en) 2015-06-09
IL204525A0 (en) 2010-11-30
BRPI0817008A2 (pt) 2017-05-16
JP5406839B2 (ja) 2014-02-05
MX2010002965A (es) 2010-09-14
CN101932723B (zh) 2014-09-10
EP2201131B1 (fr) 2014-11-05
DOP2010000076A (es) 2010-08-15
WO2009037441A1 (fr) 2009-03-26
CR11504A (es) 2011-05-10
CA2699853A1 (fr) 2009-03-26
EA017879B1 (ru) 2013-03-29
US20100280105A1 (en) 2010-11-04
WO2009037438A1 (fr) 2009-03-26
US20110287416A1 (en) 2011-11-24
ZA201001878B (en) 2011-05-25
WO2009037438A8 (fr) 2010-04-15
US20160032368A1 (en) 2016-02-04
CO6260156A2 (es) 2011-03-22
AU2008300397A1 (en) 2009-03-26
EP2198045A1 (fr) 2010-06-23
EA201000334A1 (ru) 2011-02-28
CA2699856C (fr) 2019-08-20
CN101932723A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
MA31753B1 (fr) Detection amelioree de l'expression de mage-a
Christiansen et al. DNA methylation age is associated with mortality in a longitudinal Danish twin study
Valencia et al. Comprehensive mutation analysis for congenital muscular dystrophy: a clinical PCR-based enrichment and next-generation sequencing panel
Henne et al. Analysis of structure and composition of bacterial core communities in mature drinking water biofilms and bulk water of a citywide network in Germany
CN106460068B (zh) 胃癌的检测试剂盒或装置以及检测方法
JP6722659B2 (ja) 結腸直腸癌のためのメチル化マーカー
Yu et al. Direct DNA methylation profiling using methyl binding domain proteins
JP2014524735A5 (fr)
Soares Bispo Santos Silva et al. Evaluation of DNA methylation markers and their potential to predict human aging
Pehlivan et al. NIPBL rearrangements in Cornelia de Lange syndrome: evidence for replicative mechanism and genotype–phenotype correlation
Papur et al. Mutation analysis of ATP7B gene in Turkish Wilson disease patients: identification of five novel mutations
MX2007008984A (es) Marcadores de cancer y metodos de deteccion.
Park et al. Traveller-associated high-level ciprofloxacin-resistant Salmonella enterica Serovar Kentucky in the Republic of Korea
JP2017511138A5 (fr)
Biran et al. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques
Tepper et al. A biotinylated cpFIT-PNA platform for the facile detection of drug resistance to artemisinin in plasmodium falciparum
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
Quero et al. Discriminatory usefulness of pulsed-field gel electrophoresis and sequence-based typing in Legionella outbreaks
RU2010149949A (ru) Тест-система для определения мутаций в генах фумарилацетоацетат гидролазы и альфа-1-антитрипсина человека
Pejanovic-Skobic et al. Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
US20230132088A1 (en) Detection of gene polymorphisms
Pousada et al. K198N polymorphism in the EDN1 gene in patients with pulmonary arterial hypertension
US20170204463A1 (en) Method for predicting risk of ankylosing spondylitis using dna copy number variants
ES2716391T3 (es) Método para predecir la respuesta al tratamiento con radioterapia combinada con quimioterapia basada en cisplatino